Amicus Therapeutics, Inc. (FOLD) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
FOLD Revenue Growth
Revenue Breakdown
FOLD's revenue distribution by segment and geography
By Geography
FOLD Revenue Analysis (2013–2024)
As of May 6, 2026, Amicus Therapeutics, Inc. (FOLD) generated trailing twelve-month (TTM) revenue of $598.7 million, reflecting strong growth of +19.5% year-over-year. The most recent quarter (Q3 2025) recorded $169.1 million in revenue, up 9.3% sequentially.
Looking at the longer-term picture, FOLD's 5-year compound annual growth rate (CAGR) stands at +23.7%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $528.3 million in 2024, representing a new all-time high.
When compared to Healthcare sector peers including RARE (+13.3% YoY), SRPT (-2.2% YoY), and BMRN (+9.9% YoY), FOLD has underperformed the peer group in terms of revenue growth. Compare FOLD vs RARE →
FOLD Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| FOLDCurrent | $599M | +19.5% | +23.7% | 4.7% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 SRPT | $2.2B | -2.2% | +37.9% | -29.9% | |
 BMRN | $3.2B | +9.9% | +11.6% | 16.6% | |
 IONS | $944M | +47.5% | +5.3% | -40.5% | |
 KRYS | $389M | +25.1% | - | 41.5% |
FOLD Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $528.3M | +32.3% | $475.4M | 90.0% | $24.9M | 4.7% |
| 2023 | $399.4M | +21.3% | $362.0M | 90.7% | $-77,211,000 | -19.3% |
| 2022 | $329.2M | +7.8% | $290.6M | 88.3% | $-212,120,000 | -64.4% |
| 2021 | $305.5M | +17.1% | $271.0M | 88.7% | $-206,434,000 | -67.6% |
| 2020 | $260.9M | +43.2% | $229.8M | 88.1% | $-246,998,000 | -94.7% |
| 2019 | $182.2M | +99.7% | $160.3M | 87.9% | $-304,037,000 | -166.8% |
| 2018 | $91.2M | +147.1% | $76.8M | 84.2% | $-328,777,000 | -360.3% |
| 2017 | $36.9M | +644.9% | $30.7M | 83.1% | $-441,985,000 | -1196.8% |
| 2016 | $5.0M | - | $4.1M | 83.2% | $-181,890,000 | -3668.6% |
| 2015 | $0 | -100.0% | $-1,833,000 | - | $-130,437,000 | - |
See FOLD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FOLD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare FOLD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonFOLD — Frequently Asked Questions
Quick answers to the most common questions about buying FOLD stock.
Is FOLD's revenue growth accelerating or slowing?
FOLD revenue is accelerating at +19.5% year-over-year, exceeding the 5-year CAGR of +23.7%. TTM revenue reached $599M. Growth momentum has increased versus prior periods.
What is FOLD's long-term revenue growth rate?
Amicus Therapeutics, Inc.'s 5-year revenue CAGR of +23.7% reflects the sustained expansion pattern. Current YoY growth of +19.5% is above this long-term average.
How is FOLD's revenue distributed by segment?
FOLD reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.